Allergan (AGN) Gets a Hold Rating from Cantor Fitzgerald


Cantor Fitzgerald analyst Louise Chen maintained a Hold rating on Allergan (NYSE: AGN) today and set a price target of $180. The company’s shares opened today at $189.53.

Chen commented:

“We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180.”

According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -8.0% and a 38.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Allergan is a Moderate Buy with an average price target of $201.57.

See today’s analyst top recommended stocks >>

Based on Allergan’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $473 million. In comparison, last year the company had a GAAP net loss of $726 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts